Bausch Health Companies | VRX - Equity Capital And Reserves


Bausch Health Companies reported $-802M in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Amgen USD 11.69B 2.5B Jun/2026
ANI Pharmaceuticals USD 597.21M 34.91M Jun/2026
Aurora Cannabis CAD 511.83M 24.53M Mar/2026
Bausch Health Companies USD -802M 1.26B Jun/2026
Biogen USD 18.85B 196.3M Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Canopy Growth CAD 697.59M 60.58M Mar/2026
Corcept Therapeutics USD 705.78M 67.79M Jun/2026
Danaher USD 52.58B 368M Jun/2026
Drreddys Laboratories INR 380.46B 376.31B Mar/2026
Eli Lilly USD 33.88B 2.68B Jun/2026
Gilead Sciences USD 11.74B 11.77B Jun/2026
Nektar Therapeutics USD 576.22M 486.38M Mar/2026
Novo Nordisk DKK 221.28B 18.21B Jun/2026
Pacira USD 671.98M 18.08M Jun/2026
Perrigo USD 2.52B 17M Jun/2026
Phibro Animal Health USD 361.83M 29.47M Mar/2026
Prestige Brands USD 1.92B 29.2M Jun/2026
Supernus Pharmaceuticals USD 1.03B 45.58M Jun/2026
Vertex Pharmaceuticals USD 20.25B 886M Jun/2026
Zoetis USD 3.15B 85M Jun/2026